Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes

Young Ae Kang, Tae Sun Shim, Won Jung Koh, Seung Heon Lee, Chang Hoon Lee, Jae Chol Choi, Jae Ho Lee, Seung Hun Jang, Kwang Ha Yoo, Ki Hwan Jung, Ki Uk Kim, Sang Bong Choi, Yon Ju Ryu, Kyung Chan Kim, Soojung Um, Yong Soo Kwon, Yee Hyung Kim, Won Il Choi, Kyeongman Jeon, Yong Il HwangSe Joong Kim, Hyun Kyung Lee, Eunyoung Heo, Jae Joon Yim

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Rationale: We previously showed that the choice of levofloxacin or moxifloxacin for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-TB) did not affect sputumculture conversion at 3 months of treatment. Objectives: To compare final treatment outcomes between patients with MDR-TB randomized to levofloxacin or moxifloxacin. Methods: A total of 151 participants with MDR-TB who were included for the final analysis in our previous trial were followed through the end of treatment. Treatment outcomes were compared between 77 patients in the levofloxacin group and 74 in the moxifloxacin group, based on the 2008 World Health Organization definitions as well as 2013 revised definitions of treatment outcomes. In addition, the time to culture conversion was compared between the two groups. Measurements and Main Results: Treatment outcomes were not different between the two groups, based on 2008 World Health Organization definitions as well as 2013 definitions. With 2008 definitions, cure was achieved in 54 patients (70.1%) in the levofloxacin group and 54 (73.0%) in the moxifloxacin group (P = 0.72). Treatment success rates, including cure and treatment completed, were not different between the two groups (87.0 vs. 81.1%, P = 0.38). With 2013 definitions, cure rates (83.1 vs. 78.4%, P = 0.54) and treatment success rates (84.4 vs. 79.7%, P = 0.53) were also similar between the levofloxacin and moxifloxacin groups. Time to culture conversion was also not different between the two groups (27.0 vs. 45.0 d, P = 0.11 on liquid media; 17.0 vs. 42.0 d, P = 0.14 on solid media). Patients in the levofloxacin group had more adverse events than those in the moxifloxacin group (79.2 vs. 63.5%, P = 0.03), especially musculoskeletal ones (37.7 vs. 14.9%, P = 0.001). Conclusions: The choice of levofloxacin or moxifloxacin made no difference to the final treatment outcome among patients with fluoroquinolone-sensitiveMDR-TB.

Original languageEnglish
Pages (from-to)364-370
Number of pages7
JournalAnnals of the American Thoracic Society
Volume13
Issue number3
DOIs
Publication statusPublished - 2016 Mar

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes'. Together they form a unique fingerprint.

  • Cite this

    Kang, Y. A., Shim, T. S., Koh, W. J., Lee, S. H., Lee, C. H., Choi, J. C., Lee, J. H., Jang, S. H., Yoo, K. H., Jung, K. H., Kim, K. U., Choi, S. B., Ryu, Y. J., Kim, K. C., Um, S., Kwon, Y. S., Kim, Y. H., Choi, W. I., Jeon, K., ... Yim, J. J. (2016). Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. Annals of the American Thoracic Society, 13(3), 364-370. https://doi.org/10.1513/AnnalsATS.201510-690BC